Uniform TitleWeight loss in obese subjects with and without type 2
diabetes treated with the long term appetite suppressant
NameRussell, Tammy L. (author), Shapses, Susan (chair), Watford, Malcolm (internal member), Hoffman, Daniel (internal member), Rutgers University, Graduate School-New Brunswick,
DescriptionStudies comparing weight loss between obese or overweight individuals with and without
type 2 diabetes show a decreased weight loss in those with type 2 diabetes. The exact
mechanisms promoting this discrepancy are unclear but may be related to the type and
amount of antidiabetes medication, an altered metabolism, stage of disease, and/or
presence of dysphoria. In this study, retrospective weight loss data from two doubleblind,
placebo controlled, randomized studies using the long-term appetite suppressant
AXOKINE (a modified ciliary neurotrophic factor) were compared. In the first study, a
total of 179 obese, nondiabetic subjects received placebo or AXOKINE at a 0.3 µ/kg, 1.0
µg/kg, or 2.0 µ/kg dose for 12 weeks. In the second study, 142 obese subjects with type
2 diabetes received placebo, 0.5 µg/kg or 1.0 µg/kg dose of AXOKINE for 12 weeks.
Nutritional counseling was similar for both groups however the diabetic group received
more frequent sessions. Mean weight loss between the two groups was similar with
diabetic subjects losing 3.0 ± 2.6 kg vs. 3.4 ± 2.5 kg in the nondiabetic group (1.0 µg/kg
dose of AXOKINE). The subjects with diabetes did not have any significant improvements in HbA1c (-0.34 ± 0.89%) or blood sugar levels (-15.5 ± 37.3 mg/dL) from baseline. Diabetic subjects also suffered more from diagnosed co-morbidities (55% of subjects had hypertension and 55% were dyslipidemic) and were likely to be on multiple oral hypoglycemic agents (66% of subjects). The amount of oral hypoglycemic agent did not appear to affect weight loss as those on multiple medications lost a similar amount of weight than the mean weight loss achieved by the nondiabetic subjects (3.3 ± 3.1 kg in the diabetic, multiple medication group vs. 3.4 ± 2.5 kg in the nondiabetic group). In contrast to the hypothesis that diabetic patients would lose less weight with and without AXOKINE compared to nondiabetic counterparts, these results suggest that weight loss is similar over a 12-week time period. A difference in weight loss may have been observed however with a longer study period.
Note[bibliography] Includes bibliographical references (p. 38-45).
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.